The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK)
Open accessAbstract
Anaplastic lymphoma kinase (ALK) activation has been associated with many types of human cancer. Significant efforts have been devoted to the development of ALK inhibitors to antagonize the kinase activity of ALK. Four ALK inhibitors have been approved by the FDA to date for treating patients with ALK-positive non-small cell lung cancers (NSCLC). However, drug resistance has been observed in the majority of patients treated with these inhibitors. New therapeutic strategies (e.g., compounds with novel mechanisms of action) are needed to overcome the drug resistance issue. The emerging PROTAC (Proteolysis Targeting Chimera) technology has been successfully applied to selective degradation of multiple protein targets, but not ALK. Since ALK protein levels are not important for viability in mammals, ALK PROTACs could lead to novel therapeutics with minimal toxicity. Here we report the design, synthesis and biological evaluation of novel PROTACs (degraders) of ALK. MS4077 (5) and MS4078 (6) potently decreased cellular levels of oncogenic active ALK fusion proteins in a concentration- and time-dependent manner in SU-DHL-1 lymphoma and NCI-H2228 lung cancer cells. The ALK protein degradation induced by compounds 5 and 6 was cereblon and proteasome dependent. In addition, compounds 5 and 6 potently inhibited proliferation of SU-DHL-1 cells. Furthermore, compound 6 displayed good plasma exposure in a mouse pharmacokinetic study, thus is suitable for in vivo efficacy studies. We also developed MS4748 (7) and MS4740 (8), very close analogs of 5 and 6 respectively, which are incapable to degrade the ALK fusion proteins, as negative controls. Compounds 5-8 are valuable chemical tools for investigating effects of ALK pharmacological degradation. Our study paved the way for developing the next generation of ALK PROTACs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, PROTACs were shown to be substrates for MDR1 (10, 13), suggesting that drug efflux represents a potential limitation for degrader therapies.”
From The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells (2022) · cites this paper as [13]
In the citing paper
“A number of PROTACs have been developed to target various POIs that are involved in the tumorigenesis and progression of hematologic malignancies, such as anaplastic lymphoma kinase (ALK) [5], Bcl-xL [4], BCR-ABL [6], Bruton’s tyrosine kinase (BTK) [7], BRD4 [8], CDK-6 [9], FMS-like tyrosine kinase-3 (FLT-3) [10], HDAC6 [11], and signal transducer and activator of transcription 3 (STAT3) [3].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [5]
In the citing paper
“Recently, the anaplastic lymphoma kinase (ALK) was degraded by two PROTACs based on a pomalidomide warhead targeting CRBN linked with either LDK378 (ceritinib) [79, 80] or TAE684 [79] targeting ALK.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [80]
In the citing paper
“Both PROTACs were able to reduce downstream signalling and proliferation of ALK-driven cell lines by degrading ALK [79, 80].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,428
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Proteasome inhibitors: valuable new tools for cell biologists.
Lee, D. H., & Goldberg, A. L. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01346-4 · Cited by 1,474
Cited by
Sorted by citations
Items 201–249 of 249
Knoll, N., Somay, K., Tiwari, P. B., Deniz, E., Formen, J. S. S. K., Frye, I., Nelson, E., Wolf, C., Toretsky, J. A., & Üren, A. (2026) · Cancers · doi:10.3390/cancers18152375 · Cited by 1
Zhang, Y., Tong, J., Luo, M., Sun, Y. M., & Qin, Z. (2025) · ChemistrySelect · doi:10.1002/slct.202405589 · Cited by 1
Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy
Fuchs, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90042-3.15001-7 · Cited by 1
Racioppo, B., Pechalrieu, D., Abegg, D., Dwyer, B. G., Ramseier, N. T., Hu, Y., & Adibekian, A. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-4nm88
Racioppo, B., Pechalrieu, D., Abegg, D., Dwyer, B. G., Ramseier, N. T., Hu, Y., & Adibekian, A. (2024) · ChemRxiv · doi:10.26434/chemrxiv-2024-4nm88-v2
Idegenerering i IT-bedrifter - åpenhet og nettverks betydning for idégenerering
Liafjell, T. A. (2014) · NORA - Norwegian Open Research Archives
Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance
Qiu, Y.-F., Song, L.-H., Jiang, G.-L., Zhang, Z., Liu, X.-Y., & Wang, G. (2022) · Pharmaceutical Fronts · doi:10.1055/s-0042-1758542
New Therapeutic Chemical Modalities: Compositions, Modes-of-action, and Drug Discovery
Valeur, E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00911
Delivery Systems: Miniaturised PROTAC, Nano PROTAC, and Aptamer-Based RNA PROTAC
Patel, M. P., Kalyani, H. K., Patel, K. M., Patel, B., Patel, D. H., & Patel, J. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_17
Role of PROTACs in Hematological Malignancies
Iqubal, A., Iqubal, M. K., Yadav, S., Arun, V. A., & Mishra, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_13
Mustafa, S., & Siddiquee, M. S. H. (2025) · German Journal of Pharmaceuticals and Biomaterials · doi:10.5530/gjpb.2024.4.11
Réarrangement de ALK dans le cancer pulmonaire non à petites cellules
Naulleau, G., Birsen, G., Mansuet‐Lupo, A., Leroy, K., & Wislez, M. (2025) · Bulletin du Cancer · doi:10.1016/s0007-4551(25)00161-4
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer
Zhao, K., Zhang, J., Yang, Z., Wang, R., Shi, Y., Ji, Y., Zhang, S., & Liu, M. (2025) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s527906 · Cited by 1
PROTACS- targeted protein degradation as a path to precision cancer therapeutics
Gatley, H. R., Fisher, P. B., & Das, S. K. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.08.001
Gerritz, S. W., Campbell, A.-M., Klug, D. M., & Sherman, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00074-1
Liu, H., Wang, Y.-P., Sun, Y., Li, T.-T., Guo, S., Zhang, X., Xue, W.-H., Xu, E., Meng, F., & Zhang, T. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109883
Fusion oncogenes in cancer: organoid models and novel therapeutic approaches
Bracesco, L., Hendriks, D. F. G., & Artegiani, B. (2026) · BMC Biology · doi:10.1186/s12915-026-02606-7
EML4-ALK in Non-small Cell Lung Cancer: Molecular Mechanisms and Targeted Therapies
Li, S., Bao, L., Zhou, D., & Li, D. (2026) · Technology in Cancer Research & Treatment · doi:10.1177/15330338261457490
Bharath, P., Iyer, S., Velu, A. V., & Kumar, D. T. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04910-z
Zhou, M., Li, L., Tang, X., Zhao, Y., & Zhang, W. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2718758
Biomimetic internalin B-engineered liposomes enable PROTAC delivery across endothelial barriers
Peters, J., Christe, L., Bandomir, N. C., Roth, P., Klos, F., Heitel, P., Frangakis, A. S., Gier, S., Vogel‐Kindgen, S., & Windbergs, M. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100022
Three decades of anaplastic lymphoma kinase: from physiological roles to cancer and immune evasion
Amin, H. M., Aminnia, S., Saber, M. M., Kannan, M. K., & Hung, J. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10364-9
Hofmann, N., Johann, F., Duevel, H. M., Harms, M., & Mäder, K. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108922
BindingDB (2022) · UC San Diego · doi:10.7270/q2765k17
BindingDB (2021) · UC San Diego · doi:10.7270/q23x89xq
BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.
BindingDB (2024) · UC San Diego · doi:10.7270/q27948wc
BindingDB Entry 50013121: Discovery of a PROTAC targeting ALK with in vivo activity.
BindingDB (2022) · UC San Diego · doi:10.7270/q25h7m0f
BindingDB Entry 50008003: Discovery of Selective Small Molecule Degraders of BRAF-V600E.
BindingDB (2021) · UC San Diego · doi:10.7270/q2xd1511
BindingDB Entry 50008470: Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK).
BindingDB (2021) · UC San Diego · doi:10.7270/q2s185wv
BindingDB (2024) · UC San Diego · doi:10.7270/q26977r0
BindingDB (2022) · UC San Diego · doi:10.7270/q2fb56k3
BindingDB (2022) · UC San Diego · doi:10.7270/q2ks6w6j
BindingDB (2024) · UC San Diego · doi:10.7270/q2db8660
BindingDB Entry 50016838: Update on the Development of MNK Inhibitors as Therapeutic Agents.
BindingDB (2023) · UC San Diego · doi:10.7270/q20c50t2
Metadata
- Authors
- Zhang, C., Han, X.-R., Yang, X., Jiang, B., Liu, J., Xiong, Y., & Jin, J.
- Affiliations
- Tisch Cancer Institute (US)
- ShanghaiTech University (CN)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Liu, Jing
- Xiong, Yue
- Jin, Jian
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 151
- Pages
- 304-314
- ISSN
- 0223-5234 (ISSN-L)
- PMC
- PMC5924614
- OpenAlex
- W2794623623
- Cited by
- 226
- References
- 57
- Citations by year
- 2026: 17 · 2025: 23 · 2024: 24 · 2023: 26 · 2022: 31 · 2021: 31 · 2020: 38 · 2019: 26 · 2018: 9
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U. S. National Institutes of Health (R01GM067113)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, anaplastic lymphoma kinase, cereblon ligands, proteasomal degradation, ALK fusion proteins, drug resistance, non-small cell lung cancer, ALK-positive lymphoma, pharmacokinetics, kinase inhibitors
- MeSH terms
- Anaplastic Lymphoma Kinase, Animals, Antineoplastic Agents, Humans, Lung Neoplasms, Lymphoma, Male, Drug Design, Signal Transduction, Receptor Protein-Tyrosine Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mice, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
